<DOC>
	<DOC>NCT00598780</DOC>
	<brief_summary>To evaluate over a period of 6 months the safety and the treatment satisfaction of newly prescribed levocetirizine in patients of age ≥ 2 years with persistent allergic rhinitis.</brief_summary>
	<brief_title>Evaluation of Safety of Levocetirizine in Routine Clinical Practice-non- Interventional Study</brief_title>
	<detailed_description>This is a non-interventional, prospective, post-authorization, multi-centre cohort study in patients treated with levocetirizine. The baseline data will be collected at the visit to the physician when levocetirizine is prescribed for the first time for the patient for Persistent Allergic Rhinitis. The data will then be collected during 2 visits occurring within the first 6 months of treatment, as usually scheduled in normal clinical practice in the Czech and Slovak Republics. This is after approximately 4 weeks and 6 months of treatment or earlier, if the treatment is stopped</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>diagnosis of persistent allergic rhinitis first prescription of levocetirizine for this diagnosis for this patient age ≥ 2 years indications other than those defined in inclusion criteria history of allergic or anaphylactic reactions to levocetirizine or other derivatives and excipients included</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Levocetirizine</keyword>
	<keyword>Xyzal</keyword>
	<keyword>Rhinitis allergic persistent</keyword>
	<keyword>Rhinitis nonseasonal</keyword>
</DOC>